Revolution Medicines, Inc.
RVMD
$41.88
$1.463.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 742.00K | 742.00K | 4.57M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 742.00K | 742.00K | 4.57M |
| Cost of Revenue | 558.37M | 470.64M | 419.13M | 375.11M | 369.98M |
| Gross Profit | -558.37M | -470.64M | -418.39M | -374.37M | -365.41M |
| SG&A Expenses | 108.90M | 96.72M | 87.15M | 78.71M | 71.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 789.43M | 689.52M | 628.44M | 575.98M | 531.95M |
| Operating Income | -789.43M | -689.52M | -627.70M | -575.23M | -527.39M |
| Income Before Tax | -698.26M | -600.85M | -566.72M | -522.73M | -487.80M |
| Income Tax Expenses | -753.00K | -753.00K | 343.00K | -3.52M | -3.52M |
| Earnings from Continuing Operations | -697.51 | -600.09 | -567.06 | -519.21 | -484.27 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -697.51M | -600.09M | -567.06M | -519.21M | -484.27M |
| EBIT | -789.43M | -689.52M | -627.70M | -575.23M | -527.39M |
| EBITDA | -782.75M | -683.00M | -621.56M | -569.47M | -522.04M |
| EPS Basic | -4.00 | -3.57 | -3.59 | -3.65 | -3.76 |
| Normalized Basic EPS | -2.50 | -2.23 | -2.13 | -2.19 | -2.26 |
| EPS Diluted | -4.00 | -3.57 | -3.59 | -3.65 | -3.76 |
| Normalized Diluted EPS | -2.50 | -2.23 | -2.13 | -2.19 | -2.26 |
| Average Basic Shares Outstanding | 693.89M | 670.47M | 637.90M | 580.29M | 522.03M |
| Average Diluted Shares Outstanding | 693.89M | 670.47M | 637.90M | 580.29M | 522.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |